Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
McKinsey
Merck
Colorcon
AstraZeneca

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR FLUCICLOVINE F-18


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Fluciclovine F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00562315 ↗ FACBC PET/CT for Recurrent Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 2007-10-01 Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients. This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This substance has a natural tendency to go to prostate tissue. The substance is called [18]FACBC and it is given in the form of an injection into a vein. After the substance reaches the prostate, scans called PET or Positron Emission Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound called [18]FDG is used for PET scans but this substance is eliminated by the kidneys and cannot reach the prostate. This substance called [18]FACBC is not eliminated by the kidneys and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on the prostate is cancer with scans or x-rays that are usually done. Anti-[18F]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the conventional imaging for prostate cancer. Investigators will be blinded of the intervention. This study will look at how the [18]FACBC goes into the prostate tissue and determine its ability to detect recurrent prostate cancer.
NCT00562315 ↗ FACBC PET/CT for Recurrent Prostate Cancer Completed David M. Schuster, MD Phase 2 2007-10-01 Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients. This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This substance has a natural tendency to go to prostate tissue. The substance is called [18]FACBC and it is given in the form of an injection into a vein. After the substance reaches the prostate, scans called PET or Positron Emission Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound called [18]FDG is used for PET scans but this substance is eliminated by the kidneys and cannot reach the prostate. This substance called [18]FACBC is not eliminated by the kidneys and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on the prostate is cancer with scans or x-rays that are usually done. Anti-[18F]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the conventional imaging for prostate cancer. Investigators will be blinded of the intervention. This study will look at how the [18]FACBC goes into the prostate tissue and determine its ability to detect recurrent prostate cancer.
NCT02578940 ↗ Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer Completed IND 2 Results LLC Phase 3 2015-11-01 The main aim is to assess the impact of using 18F-fluciclovine (as a PET imaging radiotracer) on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer (BCR) who are being considered for salvage treatment with the intention of providing disease cure. Also, this study will consolidate the information regarding diagnostic performance of fluciclovine PET/CT in a large number of prospectively followed patients at several centres in the UK and assess the effect of PSA level on the likelihood of detecting cancer lesions by 18F-fluciclovine
NCT02578940 ↗ Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer Completed Innovate UK Phase 3 2015-11-01 The main aim is to assess the impact of using 18F-fluciclovine (as a PET imaging radiotracer) on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer (BCR) who are being considered for salvage treatment with the intention of providing disease cure. Also, this study will consolidate the information regarding diagnostic performance of fluciclovine PET/CT in a large number of prospectively followed patients at several centres in the UK and assess the effect of PSA level on the likelihood of detecting cancer lesions by 18F-fluciclovine
NCT02578940 ↗ Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer Completed Syne Qua Non Limited Phase 3 2015-11-01 The main aim is to assess the impact of using 18F-fluciclovine (as a PET imaging radiotracer) on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer (BCR) who are being considered for salvage treatment with the intention of providing disease cure. Also, this study will consolidate the information regarding diagnostic performance of fluciclovine PET/CT in a large number of prospectively followed patients at several centres in the UK and assess the effect of PSA level on the likelihood of detecting cancer lesions by 18F-fluciclovine
NCT02578940 ↗ Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer Completed Blue Earth Diagnostics Phase 3 2015-11-01 The main aim is to assess the impact of using 18F-fluciclovine (as a PET imaging radiotracer) on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer (BCR) who are being considered for salvage treatment with the intention of providing disease cure. Also, this study will consolidate the information regarding diagnostic performance of fluciclovine PET/CT in a large number of prospectively followed patients at several centres in the UK and assess the effect of PSA level on the likelihood of detecting cancer lesions by 18F-fluciclovine
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fluciclovine F-18

Condition Name

Condition Name for Fluciclovine F-18
Intervention Trials
Prostate Cancer 7
Brain Metastases 5
Prostate Adenocarcinoma 3
Glioma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fluciclovine F-18
Intervention Trials
Prostatic Neoplasms 16
Brain Neoplasms 8
Neoplasms, Second Primary 4
Neoplasm Metastasis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluciclovine F-18

Trials by Country

Trials by Country for Fluciclovine F-18
Location Trials
United States 62
United Kingdom 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fluciclovine F-18
Location Trials
California 8
Utah 6
Pennsylvania 6
Georgia 6
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluciclovine F-18

Clinical Trial Phase

Clinical Trial Phase for Fluciclovine F-18
Clinical Trial Phase Trials
Phase 4 2
Phase 3 6
Phase 2 16
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fluciclovine F-18
Clinical Trial Phase Trials
Recruiting 16
Completed 10
Not yet recruiting 7
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluciclovine F-18

Sponsor Name

Sponsor Name for Fluciclovine F-18
Sponsor Trials
Blue Earth Diagnostics 19
National Cancer Institute (NCI) 9
Emory University 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fluciclovine F-18
Sponsor Trials
Other 42
Industry 28
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Merck
AstraZeneca
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.